行情

CELG-RT

CELG-RT

Bristol-Myers Squibb Company Celegne Contingent Value Rights
NYSE
0.1230
+0.0019
+1.57%
已收盘, 16:00 12/01 EST
开盘
0.1230
昨收
0.1211
最高
0.1230
最低
0.1230
成交量
100
成交额
--
52周最高
0.2500
52周最低
0.0373
市值
8,750.22万
市盈率(TTM)
0.0153
分时
5日
1月
3月
1年
5年
暂无数据
CELG-RT 简况
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CELG RT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CELG-RT股票基本功能。